恆大汽車(00708.HK)兩基地試產 明年將陸續量產恆馳
恆大汽車(00708.HK)公布,上海、廣州兩大生產基地已全面啟動試生產調試。
公司指,兩大基地均按照工業4.0標準建設,裝配了2,545台智慧型機器人,採用德國舒勒、庫卡、杜爾、日本發那科等世界最先進的裝備,引進世界最先進的工藝,實現世界最先進的智慧製造,全面達產後1分鐘可產1輛車,其達至到2025年實現首期規劃總產能年產100萬輛。
公司表示,旗下「恆馳」系列預計明年陸續量產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.